COMMUNIQUÉS West-GlobeNewswire

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
19/03/2026
─ Completed Successful FDA End-of-Phase 2 Meeting Following Positive Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis (PSC)─ ─Achieved Alignment with FDA on Clear and Efficient Pathway to [...]
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study
19/03/2026
MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Causeway Therapeutics Presents Data from Phase 2 Clinical Trial of TenoMiR® for Lateral Epicondylitis at RNA Leaders Europe 2026
19/03/2026
Data Show Statistically Significant Improvements in Pain, Function and Tendon Structure in Appropriately Dosed Patients TenoMiR to Progress to Phase 3 Study for Lateral Epicondylitis, Making it One of the Most Advanced [...]
Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
19/03/2026
SAN DIEGO and TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) today announced that Institutional Shareholder Services (“ISS”), a leading [...]
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
19/03/2026
Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading [...]
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
19/03/2026
Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Breakthrough Therapy Designation by the FDA [...]
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
19/03/2026
Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer’s Drug Development Boca Raton, FL, March 19, 2026 (GLOBE NEWSWIRE) -- [...]
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
19/03/2026
New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer’s disease (AD) co-pathology — experienced greater clinical benefit with neflamapimod in [...]
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
19/03/2026
Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three [...]
Picard Medical / SynCardia Highlight Second Successful Total Artificial Heart Bridge to Transplant at UCSF Health
19/03/2026
Case highlights young patient supported for 119 days with the SynCardia Total Artificial Heart before successful heart transplantation TUCSON, Ariz., March 19, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE [...]
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
19/03/2026
WASHINGTON, D.C., March 19, 2026 (GLOBE NEWSWIRE) -- NeuroRPM , a digital health company focused on Parkinson’s disease monitoring, today announced that its FDA-cleared wearable platform will be used for digital [...]
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
19/03/2026
PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable [...]
Clearmind Medicine Reports Successful Ongoing Treatment of Participants at US Sites in its FDA-approved CMND-100 Phase I/IIa Clinical Trial for Alcohol Use Disorder
19/03/2026
Vancouver, Canada, March 19, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non- [...]
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client
19/03/2026
VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing [...]
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
19/03/2026
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – AZSTARYS Expected to [...]
Cylinder Health appoints Terry Boch as CEO as demand grows for digestive health solutions
19/03/2026
Health care technology executive brings more than three decades of leadership experience and a personal connection to digestive health. CHICAGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cylinder Health today announced the [...]
TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million
19/03/2026
Additional funding provides financial flexibility to expand opportunistic share repurchases and support strategic and operational initiatives NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (“TG” or “ [...]
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
19/03/2026
Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value of earlier diagnosis using CNSide as it enters U.S. commercialization HOUSTON, March 19, 2026 [...]
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
19/03/2026
Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aR Substantial progress made toward Phase 2b readiness for izicopan in [...]

Pages